Replies to post #28107 on Marker Therapeutics Inc (MRKR)

[poods]

I think if they get another CR in Arm A in the remaining patients, it would confirm activity of the combo in PC and they would PR it. I think if presented in the context of all the data including immune responses, the market would clearly understand the CR was not chance because they are so rare with chemo alone. IMO the next CR will most likely be seen with Folfirinox, as was the first. Oxalloplatin may be a key ingredient as it produces immunogenic cell death.